Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 78Stomach Neoplasms 14Neoplasms 8Neoplasm Metastasis 8HER2-positive Breast Cancer 4Esophageal Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Brain Neoplasms 4Inflammatory Breast Neoplasms 3Breast Neoplasms, Male 3Triple Negative Breast Neoplasms 2Recurrence 2Ovarian Neoplasms 2Cardiotoxicity 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Solid Tumor 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplastic Cells, Circulating 1Myeloproliferative Disorders 1Mycosis Fungoides 1Multiple Myeloma 1Meningeal Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

tucatinib 1WP 744 1Trastuzumab 1Temozolomide 1Rituximab 1Capecitabine 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Meningeal Neoplasms × Trastuzumab × Clear all
NCT03501979 2025-08-29

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

University of Alabama at Birmingham

Phase 2 Terminated
17 enrolled 16 charts
Breast

Breast Neoplasms, Meningeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡